Marketing and supply rights for Sintetica’s drug

U.S. pharma group Harrow Health has identified great potential in a development from Ticino. According to a press release, it has acquired the marketing and supply rights in the USA and Canada for drug candidate AMP‑100, which has been developed by pharma group Sintetica based in Mendrisio.

When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections. These are estimated to total over 10 million procedures annually in the USA alone.

Sintetica recently completed a Phase 3 study that successfully compared the efficacy and tolerability of the drug candidate to current standards of care. The company intends to submit a New Drug Application to the U.S. Food and Drug Administration in late 2021.

The agreement with Harrow Health provides for upfront and milestone payments to Sintetica as well as per unit royalties on sales of AMP-100, when successfully commercialized. Harrow Health will have marketing rights for the USA and Canada alone, with Sintetica retaining the marketing rights in other countries.

“This transaction reflects Harrow Health’s commitment to continued growth by adding new high-value products to our portfolio,” said Mark L. Baum, CEO from Harrow Health. The company plans to market the drug via ImprimisRx, its ophthalmic-focused commercial and distribution platform.